Indegene Limited’s Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and half-year ending September 30, 2025. The board has also approved an investment of up to €8.5 million in equity shares of its wholly-owned subsidiary, Indegene Ireland Limited. Other approvals include share allotment under ESOP and RSU plans and an amendment to the Anti-Sexual Harassment Policy.
Financial Performance Approved
The Board of Directors has given its nod to the unaudited financial results, both standalone and consolidated, for Q2 2025. These results have been reviewed by the auditors. The details of the financial performance are available on the company website.
Investment in Indegene Ireland Limited
A significant decision made was the approval for investment in equity shares of Indegene Ireland Limited. This investment could reach up to Euro 8.5 million and will be completed in one or more tranches. This investment aims to support the subsidiary’s capital expenditure requirements, intended to expand its business.
ESOP and RSU Plans
The board has also approved the allotment of shares under the ESOP 2020 Plan and RSU 2020 Plan, rewarding and incentivizing its employees. Noted grants under the RSU 2020 Plan, ESOP 2020 Plan and CSOP 2022 were also acknowledged during the board meeting.
Policy Updates
An amendment to the Anti-Sexual Harassment Policy was approved, ensuring the company remains compliant with the latest regulations and maintains a safe and respectful working environment.
Financial Highlights (Consolidated)
Key figures from the consolidated financial results include:
- Revenue from operations: ₹8,042 million for the quarter, ₹15,650 million for the six months ended September 30, 2025.
- Profit before tax: ₹1,331 million for the quarter, ₹2,852 million for the six months ended September 30, 2025.
- Profit for the period: ₹1,021 million for the quarter, ₹2,185 million for the six months ended September 30, 2025.
Financial Highlights (Standalone)
Key figures from the standalone financial results include:
- Revenue from operations: ₹3,067 million for the quarter, ₹5,623 million for the six months ended September 30, 2025.
- Profit before tax: ₹775 million for the quarter, ₹1,373 million for the six months ended September 30, 2025.
- Profit for the period: ₹599 million for the quarter, ₹1,050 million for the six months ended September 30, 2025.
Source: BSE